{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cavosonstat", "query": { "intervention": "Cavosonstat" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 8, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-03T02:36:17.943Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02275936", "title": "Study of N91115 in Patients With Cystic Fibrosis Homozygous F508del-CFTR Mutation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "N91115", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nivalis Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 51, "start_date": "2015-02", "completion_date": "2015-07", "has_results": false, "last_update_posted_date": "2016-11-07", "last_synced_at": "2026-09-03T02:36:17.943Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02275936" }, { "nct_id": "NCT04129931", "title": "PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "MCT", "type": "DRUG" }, { "name": "Clazakizumab", "type": "DRUG" }, { "name": "Broncho-Vaxom", "type": "DRUG" }, { "name": "Imatinib Mesylate", "type": "DRUG" }, { "name": "Cavosonstat", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 950, "start_date": "2019-12-19", "completion_date": "2025-03-19", "has_results": true, "last_update_posted_date": "2026-04-01", "last_synced_at": "2026-09-03T02:36:17.943Z", "location_count": 29, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Sacramento, California + 17 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04129931" }, { "nct_id": "NCT02589236", "title": "Study of Cavosonstat (N91115) in Patients With CF Homozygous for the F508del-CFTR Mutation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "Cavosonstat", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nivalis Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 138, "start_date": "2015-11", "completion_date": "2016-12", "has_results": false, "last_update_posted_date": "2017-01-10", "last_synced_at": "2026-09-03T02:36:17.943Z", "location_count": 46, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 42 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02589236" }, { "nct_id": "NCT02724527", "title": "Study of Cavosonstat (N91115) in CF Patients Who Are Heterozygous for F508del-CFTR and a Gating Mutation and Being Treated With Ivacaftor", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "Cavosonstat", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nivalis Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2016-04", "completion_date": "2017-04", "has_results": false, "last_update_posted_date": "2016-11-21", "last_synced_at": "2026-09-03T02:36:17.943Z", "location_count": 12, "location_summary": "Denver, Colorado • Baltimore, Maryland • Boston, Massachusetts + 9 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02724527" }, { "nct_id": "NCT02500667", "title": "A Drug-Drug Interaction Study of N91115 +/- Rifampin in Healthy Adult Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Drug Interaction Potentiation" ], "interventions": [ { "name": "N91115", "type": "DRUG" }, { "name": "Rifampin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nivalis Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 15, "start_date": "2015-06", "completion_date": "2015-08", "has_results": false, "last_update_posted_date": "2016-11-07", "last_synced_at": "2026-09-03T02:36:17.943Z", "location_count": 1, "location_summary": "Lakewood, Colorado", "locations": [ { "city": "Lakewood", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02500667" }, { "nct_id": "NCT02013388", "title": "MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetic Effects of N91115 in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "N91115", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Placebo-Day 1 only", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nivalis Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 49, "start_date": "2014-02", "completion_date": "2015-02", "has_results": true, "last_update_posted_date": "2016-12-21", "last_synced_at": "2026-09-03T02:36:17.943Z", "location_count": 1, "location_summary": "Lakewood, Colorado", "locations": [ { "city": "Lakewood", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02013388" }, { "nct_id": "NCT02934139", "title": "MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Cavosonstat (N91115) in Healthy Subjects (SNO-9)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "Cavosonstat", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Nivalis Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 32, "start_date": "2016-10", "completion_date": "2017-01", "has_results": false, "last_update_posted_date": "2017-01-31", "last_synced_at": "2026-09-03T02:36:17.943Z", "location_count": 1, "location_summary": "Lakewood, Colorado", "locations": [ { "city": "Lakewood", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02934139" }, { "nct_id": "NCT02227888", "title": "PK Study of N91115 in Cystic Fibrosis Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "N91115", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nivalis Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2014-10", "completion_date": "2015-01", "has_results": false, "last_update_posted_date": "2016-11-07", "last_synced_at": "2026-09-03T02:36:17.943Z", "location_count": 3, "location_summary": "Birmingham, Alabama • Aurora, Colorado • Denver, Colorado", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02227888" } ] }